| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working … MH Jagasia, HT Greinix, M Arora, KM Williams, D Wolff, EW Cowen, ... Biology of Blood and Marrow Transplantation 21 (3), 389-401. e1, 2015 | 2866 | 2015 |
| Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation NS Majhail, SH Farnia, PA Carpenter, RE Champlin, S Crawford, ... Biology of Blood and Marrow Transplantation 21 (11), 1863-1869, 2015 | 535 | 2015 |
| Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD … J Pidala, B Kurland, X Chai, N Majhail, DJ Weisdorf, S Pavletic, C Cutler, ... Blood, The Journal of the American Society of Hematology 117 (17), 4651-4657, 2011 | 420 | 2011 |
| Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria S Arai, M Jagasia, B Storer, X Chai, J Pidala, C Cutler, M Arora, ... Blood, The Journal of the American Society of Hematology 118 (15), 4242-4249, 2011 | 249 | 2011 |
| Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy AS Kanate, NS Majhail, BN Savani, C Bredeson, RE Champlin, ... Biology of Blood and Marrow Transplantation 26 (7), 1247-1256, 2020 | 236 | 2020 |
| Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation KM Williams, GS Cheng, I Pusic, M Jagasia, L Burns, VT Ho, J Pidala, ... Biology of Blood and Marrow Transplantation 22 (4), 710-716, 2016 | 207 | 2016 |
| Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation M Arora, CS Cutler, MH Jagasia, J Pidala, X Chai, PJ Martin, ... Biology of Blood and Marrow Transplantation 22 (3), 449-455, 2016 | 169 | 2016 |
| Personalizing busulfan-based conditioning: considerations from the american society for blood and marrow transplantation practice guidelines committee J Palmer, JS McCune, MA Perales, D Marks, J Bubalo, M Mohty, ... Biology of Blood and Marrow Transplantation 22 (11), 1915-1925, 2016 | 158 | 2016 |
| Tocilizumab for the treatment of steroid refractory graft-versus-host disease WR Drobyski, M Pasquini, K Kovatovic, J Palmer, JD Rizzo, A Saad, ... Biology of Blood and Marrow Transplantation 17 (12), 1862-1868, 2011 | 149 | 2011 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 144 | 2023 |
| Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium DA Jacobsohn, BF Kurland, J Pidala, Y Inamoto, X Chai, JM Palmer, ... Blood, The Journal of the American Society of Hematology 120 (13), 2545-2552, 2012 | 136 | 2012 |
| Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia N Ertz-Archambault, H Kosiorek, GE Taylor, K Kelemen, A Dueck, ... JAMA oncology 3 (7), 936-943, 2017 | 115 | 2017 |
| Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft … J Pidala, G Vogelsang, P Martin, X Chai, B Storer, S Pavletic, DJ Weisdorf, ... Haematologica 97 (3), 451, 2012 | 114 | 2012 |
| Validation of measurement scales in ocular graft-versus-host disease Y Inamoto, X Chai, BF Kurland, C Cutler, MED Flowers, JM Palmer, ... Ophthalmology 119 (3), 487-493, 2012 | 103 | 2012 |
| Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality J Pidala, T Wang, M Haagenson, SR Spellman, M Askar, M Battiwalla, ... Blood, The Journal of the American Society of Hematology 122 (22), 3651-3658, 2013 | 99 | 2013 |
| A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation S Arai, J Pidala, I Pusic, X Chai, S Jaglowski, N Khera, J Palmer, GL Chen, ... Clinical Cancer Research 22 (2), 319-327, 2016 | 96 | 2016 |
| Clinical relevance of natural killer cells following hematopoietic stem cell transplantation JM Palmer, K Rajasekaran, MS Thakar, S Malarkannan Journal of Cancer 4 (1), 25, 2012 | 95 | 2012 |
| Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft … J Palmer, K Williams, Y Inamoto, X Chai, PJ Martin, LH Santo Tomas, ... Biology of Blood and Marrow Transplantation 20 (3), 337-344, 2014 | 89 | 2014 |
| Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant GS Cheng, B Storer, JW Chien, M Jagasia, JJ Hubbard, L Burns, VT Ho, ... Annals of the American Thoracic Society 13 (11), 1932-1939, 2016 | 88 | 2016 |
| Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis AT Gerds, MR Savona, BL Scott, M Talpaz, M Egyed, CN Harrison, ... Blood Advances 4 (22), 5825-5835, 2020 | 81 | 2020 |
